Forager's 120% Premium for Quipt Would Set M&A Benchmark; Board's Inaction Erodes Shareholder IRR

Forager Capital Management, a significant shareholder of Quipt Home Medical Corp. with a 9.7% stake, has voiced dissatisfaction with the Quipt Board's inaction following its acquisition offer of $3.10 per share, presented on May 17, 2025. Forager emphasizes that had the Board engaged constructively, the transaction could have been finalized within the proposed timeframe, providing shareholders with a remarkable 120% return in under six months. This potential gain represents a financial opportunity that shareholders could have already reinvested into new ventures.

According to a report by Houlihan Lokey, take-private transactions in 2024 averaged a 37.5% premium, with a peak of 106%. Forager’s offer of a 120% premium substantially outstrips both the average and the highest premiums reported, illustrating the significant value being offered to shareholders. The firm argues that every day the Board delays the decision reduces the Internal Rate of Return (IRR) for shareholders, a critical measure of performance.

Forager remains committed to realizing a transaction that would provide immediate value for all Quipt shareholders. Importantly, the firm has indicated a willingness to enhance its offer if the Board initiates constructive discussions. This scenario raises questions about the Board's strategic direction and commitment to shareholder value, especially in light of the compelling valuation presented.

In conclusion, Forager's strong stance on pursuing the acquisition of Quipt underscores the growing tension between shareholders seeking optimal returns and a Board's governance approach. The outcome will possibly set a standard for future mergers and acquisitions, particularly concerning how shareholder interests are prioritized in such decisions.

Forager Capital Management’s aggressive stance regarding its acquisition proposal for Quipt Home Medical Corp. marks a significant moment for shareholders. With a proposed price of $3.10 per share—a hefty 120% premium above prior unaffected market prices—Forager is setting a high benchmark for M&A activity. This unprecedented offer not only highlights the value that Forager sees in Quipt but also underscores the potential for value erosion if the company's board remains inactive.

The analysis shows that while the average premium for take-private transactions in 2024 was approximately 37.5%, and peaked at 106%, Forager’s proposal significantly outstrips these figures. This serves as a stark reminder of the urgency for Quipt’s board to engage with its largest shareholder, especially when considering the implications of delaying the transaction. The longer the board waits, the more shareholder Internal Rate of Return (IRR) diminishes, an essential metric that reflects the effectiveness of investment management.

For shareholders, the inability of the board to act constructively threatens not only immediate financial gains but also sets a precedent for future M&A negotiations. A delay could deter potential investors wary of a board unwilling to capitalize on strategic opportunities. Furthermore, Forager has indicated a willingness to enhance their offer, suggesting that constructive dialogue could unlock further value for shareholders.

Investors should closely monitor the communications between Forager and Quipt’s board, as any movement—or lack thereof—will likely dictate the stock's near-term performance. In light of Forager's proposal, shareholders would be prudent to consider their positions: advocating for board engagement or, if the inaction persists, seeking alternative investments that better align with their growth objectives. In summary, active stewardship and decisive action from Quipt’s board are critical in navigating this M&A landscape effectively.